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The conventional antihypertensive therapies including renin–angiotensin–aldosterone system antagonists (converting enzyme inhibitors,
receptor blockers, renin inhibitors, and mineralocorticoid receptor blockers), diuretics, b-blockers, and calcium channel blockers are variably
successful in achieving the challenging target blood pressure values in hypertensive patients. Difﬁcult to treat hypertension is still a commonly
observed problem world-wide. A number of drugs are considered to be used as novel therapies for hypertension. Renalase supplementation,
vasopeptidase inhibitors, endothelin antagonists, and especially aldosterone antagonists (aldosterone synthase inhibitors and novel selective
mineralocorticoid receptor blockers) are considered an option in resistant hypertension. In addition, the aldosterone antagonists as well as
(pro)renin receptor blockers or AT2 receptor agonists might attenuate end-organ damage. This array of medications has now been com-
plemented by a number of new approaches of non-pharmacological strategies including vaccination, genomic interference, controlled breath-
ing, baroreﬂex activation, and probably most successfully renal denervation techniques. However, the progress on innovative therapies seems
to be slow and the problem of resistant hypertension and proper blood pressure control appears to be still persisting. Therefore the regi-
mens of currently available drugs are being ﬁne-tuned, resulting in the establishment of several novel ﬁxed-dose combinations including triple
combinations with the aim to facilitate proper blood pressure control. It remains an exciting question which approach will confer the best
blood pressure control and risk reduction in this tricky disease.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Despite the recent and substantial advances in the treatment of
hypertension, the majority of patients still remains not optimally
controlled; hence, the need for innovative strategies to lower
blood pressure (BP). The current BP target values are fairly aggres-
sive, often requiring the addition of a 4th or 5th agent, ultimately
taxing the imagination of even the most skilled physician and redu-
cing drug compliance in a large proportion of patients.
Any innovation in antihypertensive therapy is generally judged
based on: (i) the capability to improve BP control; (ii) the effective-
ness in treatment resistant hypertension; (iii) potential for further
(beyond BP control) risk reduction, by impact on the associated
functional, metabolic, and structural alterations.
1 While this issue
is highly debated, the most part falls on the side of tight BP
control rather than a speciﬁc treatment.
2 Novel approaches to
hypertension treatment include: (i) drug-based strategies targeting
traditional (e.g. the renin–angiotensin–aldosterone system, RAAS)
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pathways; (ii) unique approaches involving gene and vaccine thera-
pies; and (iii) device-based therapies (baroreceptor sensitization or
renal nerve ablation).
1,3,4 We provide an overview of various thera-
pies in development (Table 1) and outline prospects how and
which of them might impact clinical care.
The renin–angiotensin–aldosterone
system
Physiology of the
renin–angiotensin–aldosterone system
The pharmacological RAAS inhibition reduces BP and represents a
keypartofcurrent approachesto cardiovascular(CV)riskreduction.
The classical simpliﬁed RAAS image has recently turned to a
complex network (Figure 1). The cascade starts with the renal
release of the renin, which cleaves the liver-produced angiotensino-
gen to angiotensin I (Ang I).
5 Renin may also bind to its (pro)renin
receptor (P)RR,
6 that enhances its cleavage activity and activates its
inactive precursor,prorenin. However,binding to(P)RR elicitsangio-
tensin-independent effects, such as activation of promyelocytic zinc
ﬁnger (PLZF), protein-phosphatidylinositol-3-kinase and eventually
mitogen-activated protein kinases (MAPKs) resulting in enhanced
proteosynthesis, proliferation, and decreased apoptosis.
7–9
Angiotensin I (Ang I; Ang 1–10) formed by renin activity is
hydrolysed by the circulating and locally expressed angiotensin-
converting enzyme (ACE) to the active angiotensin II (Ang II;
Ang 1–8). Angiotensin-converting enzyme also inactivates bradyki-
nin with its nitric oxide (NO)- and prostacyclin (PGI2) stimulating
and vasodilative activity.
5 Ang II formation may take place indepen-
dently of ACE via the enzymatic activity of chymase, carboxypep-
tidase, cathepsin G, or tonin.
10 In fact, Ang I catabolism is even
more complex. Neutral endopeptidase (NEP) can cleave Ang I
to Ang 1–7,
11 which may be formed by an ACE homologue,
ACE2, via Ang 1–9 or directly from Ang II as well.
12 While Ang
(1–7) is degraded by ACE to Ang (1–5), Ang II is degraded to
Ang III and IV by aminopeptidase A (AMPA) and M (AMPM),
respectively.
13 The different cleavage products then elicit various
receptor afﬁnities.
Angiotensin type 1 receptor (AT1R) mediates most of the Ang II
effects, which might be partially opposed by type 2 receptor (AT2R).
Angiotensin III (Ang 2–8) displays afﬁnity to AT1Ra n dA T 2Ra sw e l l .
AT2R is also activated by Ang (1–9), while Ang (1–7) stimulates the
Masreceptor
14andpossiblytheAT2R.
15Finally,AngIV(Ang3–8)acti-
vates the AT4R or insulin-regulated aminopeptidase.
16
The AT1R mediates, among others, vasoconstriction, inﬂam-
mation, myocardial and vascular hypertrophy, and ﬁbrosis. It is
one of the triggers [along with adrenocorticotropic hormone
(ACTH), antidiuretic hormone, catecholamines, endothelin, sero-
tonin, or Mg
2+ and K
+ levels] of aldosterone release, which con-
tributes to Na
+ retention and cardiac, vascular, and glomerular
remodelling (Figure 2A).
17
The AT2R, inhibits MAPKs, activates NO/cGMP and phospho-
lipase A2 pathways, mediating thus anti-proliferation, vasodilation,
and anti-inﬂammation.
18–21 The pharmacological stimulation of
AT2R with the recently discovered non-peptide agonist, compound
21, improved myocardial function in rats with myocardial infarction
independently of BP effects
22 but along with anti-inﬂammatory
action and NF-kB inhibition.
23
Mas may also partially antagonize the AT1R effects. It promotes
Akt phosphorylation,
24 NO release,
25 vasodilation,
14 and anti-
inﬂammation.
26 Mas stimulation with a synthetic peptide induced
vasorelaxation, reduced BP in spontaneously hypertensive rats
(SHR) and showed antiarrhythmic effects
27 suggesting some thera-
peutic potential.
Finally, AT4R stimulation results in proinﬂammatory effects
13
with possible negative impact.
This complex puzzle of the ‘novel RAAS’ complicates our under-
standingofmechanismsparticipatingintheeffectsofRAAS-interfering
drugs, but it offers new and promising drug targets, as well; rendering
the RAAS far from being fully exploited.
...............................................................................................................................................................................
Table 1 Number of selected compounds in development
Mechanism Approved In clinical/late
preclinical phase
Note
Angiotensin-converting enzyme inhibitors 0 2 Includes imidapril approved in Japan; and NO-releasing enalapril
AT1 receptor blockers 3 3 Does not include compounds with dual action
Anti RAAS vaccines 0 2
AT2 receptor agonists 0 1
Vasopeptidase inhibitors 0 4 Including compounds with dual action
Aldosterone antagonists 1 3
Calcium channel blockers 1 1
b-Blockers 1 0 Includes nebivolol, NO-releasing blocker
Endothelin antagonists 0 3 Including compounds with dual action
Double combinations 7 5
Triple combinations 3 0
Number of compounds approved by FDA since 2000 and identiﬁed compounds in clinical/late preclinical phase
1 for 1 February 2011.
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Angiotensin-converting enzyme inhibitors and AT1R blockers are
in the centre of the current gold standard for cardioprotective
therapies. Their beneﬁcial effects are attributed to inhibition of
the undesired AT1R stimulation and subsequent reduction in vas-
cular tone, BP, aldosterone, vasopressin and catecholamines
release, inhibition of inﬂammation, and attenuation of cell
growth. There is a clear evidence for this approach given by clinical
trials with ACE-Inhibitors (CAPP
28, STOP-2
29, HOPE
30) and AT1R
blockers (LIFE
31, VALUE
32). The later leave the AT2R unopposed
for on-going Ang II stimulation and do not interfere with bradykinin
catabolism, which is held responsible for the development of
angioedema after ACE inhibition. When telmisartan was compared
with ramipril (ONTARGET) it was non-inferior in terms of efﬁcacy
and better tolerated (lower incidence of dry cough and angioe-
dema) in high-risk patients.
33 Both ACE-Inhibitors and AT1R antag-
onists reduce the onset of new diabetes mellitus
34,35 and some
AT1R blockers, i.e. telmisartan or losartan with its metabolite
Figure 1 The interplay of recently discovered components of the renin–angiotensin–aldosterone system. The protease renin cleaves angio-
tensinogen to angiotensin I, which is then hydrolyzed by the circulating and local angiotensin-converting enzyme to the active angiotensin II.
Angiotensin II may by alternatively formed by chymase, carboxypeptidase, cathepsin G, or tonin. Angiotensin I might also be directly (by
neutral endopeptidase) or indirectly (by angiotensin-converting enzyme and angiotensin-converting enzyme 2 with angiotensin 1–9 as inter-
mmediate product) converted to angiotensin 1–7. Angiotensin 1–7 is degraded by angiotensin-converting enzyme to angiotensin 1–5 while
angiotensin II is degraded to angiotensin III and IV by aminopeptidase A and M. Receptors of the renin–angiotensin–aldosterone system
include the (pro)renin receptor that enhances the activity of renin, activates prorenin, and elicits angiotensin-independent effects as well.
The deleterious effects of renin–angiotensin–aldosterone system activation are ascribed to angiotensin type 1 receptors stimulation by angio-
tensin II and III. The modestly researched angiotensin type 4 receptor (insulin-regulated aminopeptidase), which is stimulated by angiotensin IV,
exerts negative effects too. On the other hand, the stimulation of the angiotensin type 2 receptor, which binds angiotensin II, angiotensin 1–9,
and angiotensin III, and Mas receptor, which binds angiotensin 1–7, seem to ellicit beneﬁcial effects. AT1R, angiotensin type 1 receptor; AT2R,
angiotensin type 2 receptor; AT4R, angiotensin type 4 receeptor; ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2;
AMPA, aminopeptidase A; AMPM, aminopeptidase M; NEP, neutral endopeptidase; IRAP, insulin-regulated aminopeptidase; (P)RR, (pro)renin
receptor; ROS, reactive oxygen species.
Therapeutic perspectives in hypertension 2741Figure 2 The therapeutic options for aldosterone antagonism. Aldosterone synthase is activated by several factors including angiotensin type
1 receptor stimulation, adrenocorticotropin release and high plasmatic K
+ concentrations. The synthetized aldosterone activates the minera-
locorticoid receptor with its epithelial and non-epithelial effects. The epithelial effects include the activation of epithelial Na
+ channel with sub-
sequent Na
+ and water retention; while the non-epithelial effects are participate in tissue remodelling and organ damage. In low aldosterone
conditions, the mineralocorticoid receptor might be activated by cortisol as well. The traditional aldosterone antagonist spironolactone
antagonises not only the mineralocorticoid receptor receptors but also the androgenic receptors leading to its anti-androgenic side. More
recent therapeutic interventions include the inhibition of aldosterone by aldosterone synthase inhibitors; more selective (compared with spir-
onolactone) blockade of mineralocorticoid receptor by eplerenone and ﬁnally epithelial Na
+ channel blockade by amiloride. (A) Recently
several dihydropyridine calcium channel blockers were reported to antagonize the mineralocorticoid receptor and to partially block T-type
voltage-dependent calcium channels in addition to the blockade of L-type voltage-dependent calcium channel. Therofore, the dihydropyridine
structure might be exploited to design non-steroid compounds with dual aldosterone antagonism+L-type voltage-dependent calcium channel
blockade (B). ACTH, adrenocorticotropic hormone; AR, androgen receptor; ANP, atrial natriuretic peptide; ASI, aldosterone synthase inhibi-
tors; AT1R, angiotensin type 1 receptor; ENaC, epithelial sodium channel; MAPK, mitogen-activated protein kinase; MR, mineralcorticoid recep-
tor; ROS, reactive oxygen species; VDCC, voltage-dependent calcium channel.
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have peroxisome proliferator-activated receptor-g activating
properties.
36,37
Further search for a beneﬁt beyond AT1R antagonism can be
expected to lead to devising multifunctional agents that combine
AT1R blocking activity with a NO-releasing moiety, NEP inhibition,
or endothelin antagonism.
38
Renin as a target
Renin, catalysing the rate limiting step in the RAAS cascade, rep-
resents a very attractive therapeutic target that was recently
exploited by the introduction of the ﬁrst-in-class selective renin
inhibitor, aliskiren. Renin inhibition is indeed associated with the
attenuation of Ang I and Ang II levels
39 and BP reduction.
40
Aliskiren reduced BP comparably to b-blockers1,
41 diuretics,
42
ACE–Inhibitors,
43,44 and AT1R blockers.
40,45 The possible beneﬁt
in renin inhibition might reside in the attenuation of plasma renin
activity which is increased by ACE inhibition or AT1R blockade.
46
On the other hand, the high renin levels after aliskiren treatment
47
might escape from renin inhibition and aliskiren may not prevent
binding of renin to the (P)RR.
48 A large clinical study programme,
named Aspire Higher, is currently underway to determine whether
aliskiren treatment ameliorates target-organ damage and positively
affects CV morbidity and mortality.
The far from optimal pharmacokinetic properties of aliskiren
(2–7% bioavailability)
39 and a ceiling dose of 300 mg daily (due
to gastrointestinal irritation) invite novel agents in this class to
the pipelines.
Prorenin receptor
The binding of (pro)renin to the (P)RR
6 up regulatesthe transform-
ing growth factor-b1, plasminogen activator inhibitor-1, ﬁbronectin,
and collagen expression,
49 enhances protosynthesis, proliferation,
anddecreasesapoptosis;
7,8besidetheeffectson(pro)renincatalytic
efﬁciency itself. Because aliskiren does not inhibit the activation of
the (P)RR by (pro)renin
48,50 the speciﬁc blockade of (P)RR could
not only reduce the enzymatic activity but also prevent some
Ang-independent effects of renin. A handling region peptide (HRP)
inhibitingthebindingofproreninto(P)RR,completelyabolisheddia-
betic nephropathy
51 even in AT1R knockout mice.
52 It also reduced
cardiacﬁbrosisinstroke-proneSHR
53and—asobservedbyaninde-
pendent group—reduced cardiac hypertrophy and ﬁbrosis in SHR
fed high-salt diet.
54 Moreover, the effects on left ventricular hyper-
trophy in diabetic SHR were additive with the effects of imidapril
and seemed to be independent of Ang II levels.
55 However, in rats
overexpressing renin and angiotensinogen, the HRP failed to
ameliorate target-organ damage in contrast to aliskiren.
56 These
partially contradictory data might be explained by different models
(the HRP were only effective in low-renin conditions
57,58)o r
by degradation/insufﬁcient bioavailability of the decoys. Further-
more, beneﬁcial effects of the HRP in vivo were shown in a
model of metabolic syndrome
59 as well as regarding diabetic
retinopathy.
60,61
The speciﬁcity of HRP binding to the (P)RR was recently shown
by label-free interaction analysis.
62 Nevertheless, some authors
suggest, that HRP might be in fact a partial agonist on the
(P)RR,
63 while others reported that the HRP effects might be
(P)RR-independent (HRP did not inhibit renin binding and signalling
and it was binding even to cells not expressing the (P)RR in vitro).
56
The development of a non-peptide (P)RR antagonist (i.e. a renin/
prorenin receptor blocker, RERB) could shed more light on the
role of (P)RR in the development of CV damage and on the poten-
tial of its therapeutic inhibition.
9 Finally, RERBs might also exert
beneﬁcial effects in cancer considering, e.g. the proproliferative
effects of the (P)RR
8 and the seminal observation that this recep-
tor is essential for Wnt signalling.
64
Vasopeptidase inhibitors
Beside ACE there are other metallopeptidases that convert vaso-
active substances, such as ACE2, NEP, or endothelin-converting
enzyme (ECE-1). Recent ﬁndings indicate a great potential for
combined ACE/ECE inhibitors,
65 but most research was devoted
to the role of NEP and the therapeutic potential of its inhibition.
Neutral endopeptidase substrates belong to vasodilators as well
as vasoconstrictors and the effect of NEP inhibition on BP is there-
fore very modest and variable.
66 On the other hand, the effect of
reduced degradation of vasodilative substances after NEP inhibition
might prevail in conditions, when the formation or action of the
vasoconstrictors is already blocked. In addition, the design of mol-
ecules inhibiting both ACE and NEP is very feasible. One of the
most studied vasopeptidase inhibitors, omapatrilat, reduced BP in
several models of experimental hypertension
67–69 as well as in
hypertensive subjects,
70 similarly to sampatrilat.
71 The trials
OCTAVE and OVERTURE supported the beneﬁt of ACE/NEP inhi-
bition in hypertension and heart failure, but they reported a higher
incidence of angioedema in patients on dual inhibition.
72,73 The
most likely explanation is the convergence of both vasopeptidases
on bradykinin degradation.
66 Therefore the dual AT1R/NEP antag-
onism (angiotensin receptor and neprilysin inhibitors, ARNI) could
show a more favourable tolerance proﬁle. Indeed, LCZ696, a
ﬁrst-in-class ARNI, reduced BP additionally to the effect of valsar-
tan, without being associated with occurrence of angioedema in a
Phase II study in mild to moderate hypertensive patients.
74 Further-
more, ARNIs cause increased natriuretic peptide concentrations.
In primates, natriuretic peptides lead to lipolysis, a fact that
might be therapeutically exploited but that also calls for careful
characterization of these effects.
75
Aldosterone receptor antagonists
Spironolactone and eplerenone are mineralocorticoid-receptor
blocking agents (MRAs) used for to block the epithelial and
non-epithelial actions of aldosterone. These compounds reduce
BP,
76–78 diminish urine protein excretion,
79,80 and confer CV
gain in heart failure apparently independently of volume altera-
tions.
81–83 The use of MRAs in the treatment of hypertension
and, in particular, resistant hypertension has stepped up over the
past decade with the growing appreciation for the role of aldoster-
onism in this disease state.
84,85 In addition, there is an evolving
understanding of aldosterone as a downstream effector for some
BP-independent Ang II-mediated unfavourable effects.
86
The BP reduction after spironolactone is conferred similarly in
hypertensives with and without primary aldosteronism (though
here higher dose is required), independently of ethnicity and
urinary aldosterone excretion and it occurs within weeks and
Therapeutic perspectives in hypertension 2743persistsindeﬁnitely.
76Spironolactonemightalsoreducetheapnoea-
hypopnea index in patients with resistant hypertension and sleep
apnoea.
87 In head-to-head comparison with spironolactone, eplere-
none shows comparable BP reduction in the treatment of essential
or hyperaldosteronism-associated hypertension.
77,88,89 However,
the mg-for-mg BP-lowering effect of eplerenone is lower than that
of spironolactone, with 200 mg eplerenone b.i.d. required to
achieve BP reduction comparable with 50 mg spironolactone b.i.d.
(thatproduces1.3–2timesgreaterreductionthansameeplerenone
dosage).
77,90
Spironolactone has gained considerable traction for use in resist-
ant hypertension, but its poor selectivity for mineralocorticoid
receptors (MR) often results in progesterone and testosterone-
dependent adverse effects, such as loss of libido, menstrual irregu-
larities, painful enlargement of the breasts with nipple tenderness,
and gynaecomastia. Eplerenone is much less frequently associated
with these adverse conditions and might serve as a substitute for
spironolactone in patients with gynaecomastia.
89 However, hyper-
kalaemia (possibly life threatening) occurs with all MRAs and
should always be anticipated.
90
Recently, some Ca
2+ channel blockers were reported to
antagonize the MR as well.
91 This action, speciﬁc to dihydropyri-
dine derivates (e.g. nimodipine), might explain their beneﬁcial
effect on cerebral ischaemia and stroke.
91 Molecules with dual
action on MR and Ca
2+ channels might represent a novel and
interesting approach to reduce BP and prevent/treat hypertensive
end-organ damage. Moreover, they antagonized the MR even in
S810L mutant form that is insensitive to spironolactone or epler-
enone.
91 This ﬁnding highlighted the possibility to develop dihydro-
pyridines with more potent and selective action on the MR. Some
such compounds (WO2005097118; DE102005034267, BR-4628)
are already in development
91–93 and they might evolve to a puta-
tive non-steroid generation of MRAs.
Aldosterone synthase inhibitors
Another approach to antagonise aldosterone is to inhibit its for-
mation and hence prevent the reactive increase in aldosterone
levels and their MR-independent effects. Several aldosterone
synthase (CYP11B2) inhibitors are being developed.
Fadrozole, an aromatase inhibitor or its dextroenantiomer
(FAD286) has been shown to inhibit aldosterone synthase and
to reduce mortality, cardiac hypertrophy, albuminuria, cell inﬁltra-
tion, and matrix deposition in the kidney in double transgenic renin
rats (dTGR), yet without a profound effect on BP.
94 Similarly in
Dahl salt-sensitive rats: intracerebroventriculary applied spirono-
lactone fully eliminated the salt-diet-related increase in BP;
whereas, FAD286 only prevented 30 mmHg of the 50 mmHg
increase.
95 FAD286 and MRAs comparably reduced hypertrophy
and interstitial ﬁbrosis of the kidney and heart induced by Ang II
and a high-salt intake.
96
Another agent, LCI699, reduced 24 h-ambulatory systolic BP by
24.1 mmHg after 4 weeks of treatment but it effectively sup-
pressed supine plasma aldosterone concentrations in a trial on
14 patients with primary aldosteronism. Although, plasma cortisol
concentrations did not change, the ACTH concentrations were
elevated, the plasma cortisol response to an ACTH stimulation
was blunted and the plasma potassium concentration was
increased.
97
The clinical goal for the aldosterone-synthase inhibitors is to be
as good as MRAs for BP reduction but better tolerated. The avail-
able information would suggest that LC1699 is but modestly effec-
tive in patients with primary aldosteronism
97 while 1 mg LCI699
was not superior in BP reduction to eplerenone 50 mg in patients
with stage 1 and 2 hypertension.
98 Future studies constructing a full
dose–response relationship could determine the clinical signiﬁ-
cance of LCI699 effect on cortisol homeostasis, and categorize
any BP-independent organ-speciﬁc effects.
99,100 However, the
development of LCI699 was stopped in the 2nd quarter of 2010
in favour of seeking more speciﬁc inhibitors.
Besides being reported to antagonize the MR,
91 several dihydro-
pyridine Ca
2+ channel blockers block T-type channel as well,
which brings upon the inhibition of aldosterone synthesis in
vitro.
101–103 However, the speciﬁcity and potency for aldosterone
synthase blockade in vivo is difﬁcult to estimate. Nevertheless,
the dihydropiridine structure might be the base for the develop-
ment of novel molecules that dually block aldosterone synthase
and MR for more potent aldosterone antagonism+they inhibit
the L-type Ca
2+ channel for more pronounced antihypertensive
effects (Figure 2B).
Endothelin system
From the endothelin (ET-1, ET-2, and ET-3) polypeptide family is
ET-1, the most clinically pertinent isoform, which was identiﬁed
in 1988 as a potent vasoconstrictor. It plays a prominent role in
ﬁbrogenesis, inﬂammation, oxidative stress, atherosclerosis, salt
and water homeostasis, and pulmonary artery hypertension as
well.
104–106
Endothelin receptor A (ETA) and B (ETB) antagonists have been
studied in resistant hypertension with darusentan (ETA/ETB antag-
onist) being the one most extensively evaluated.
107,108 In patients
with resistant hypertension, darusentan met the end-points for sys-
tolic and diastolic BP in the DAR-311 (DORADO) trial,
107 and it
produced a greater reduction in mean 24-h systolic and diastolic
BP than either placebo or the central a2-agonist, guanfacine, in
the DAR-312 (DORADO-AC) trial.
108 However, there was an
unexplained BP reduction at Week 14 in the placebo arm
108 and
the development of darusentan has been put on hold.
Endothelin antagonists have only been approved for use in pul-
monary artery hypertension and their future for the treatment of
hypertension is not particularly bright. The most pronounced stick-
ing points with endothelin antagonistsinclude prominent side-effect
proﬁle (salt and water retention and peripheral oedema),
107–110
high teratogenicity potential(FDA Pregnancy Category X), and pro-
pensity to dose-dependent transaminitis.
110 Moreover, the results
from trials in heart failure, chronic kidney disease, cerebral vasos-
pasm, and erectile dysfunction were not very encouraging.
The most pertinent questions for the next generation of
endothelin-receptor antagonists are: (i) could superiority to ETA/
ETB antagonists in BP reduction or tolerance be achieved by design-
ing selective ETA antagonists or dual AT1R/ETA antagonists ,[e.g.
PS433540
111 (Ligand Pharmaceuticals (San Diego, CA, USA))]; (ii)
will these molecules have a differing dose range for BP-dependent
T. Unger et al. 2744and -independent tissue effects; (iii) will, in these compounds, the
dose-dependent oedema still limit reaching a truly effective dose;
(iv) might these drugs compete with aldosterone antagonists,
which are now fast becoming the treatment of choice for resistant
hypertension?
Renalase system
Recently, in an extensive search for vasoactive kidney-related pro-
teins, a novel catecholamine peptidase, renalase, was discov-
ered.
112 Its basal plasmatic activity is very low, but it can be
increased by catecholamines,
113 which it in turn metabolizes.
112
Kidneys are probably the major source of circulating renalase as
in subnephrectomized rats or in patients with end-stage renal
failure the renalase production in the heart, muscle, or liver
could not compensate the deﬁcit of kidney-produced rena-
lase.
112,113 Renalase down-regulation or knock-out is associated
with increased catecholamine levels, BP and higher susceptibility
to ischaemic myocardial damage,
114–116 which are prevented by
supplementation with recombinant renalase.
116 Because one rena-
lase polymorphism was associated with essential hypertension
117
and increased CV risk in patients with coronary heart disease,
115
certain patients might be identiﬁed that could especially beneﬁt
from renalase substitution.
Although some concerns due to the metabolization of the renal
vasodilator dopamine by renalase
118 were raised, no alterations in
renal function were observed in renalase knock-outs sup-
plemented with recombinant enzyme.
116 Regardless of the thera-
peutic potential and safety of renalase administration, its
discovery might have provided a novel important pathophysiologi-
cal link between the kidney, sympathetic tone, and BP.
Gene-based therapies
The pharmacological approaches, including the investigational
ones, represent ‘only’ a possible treatment option for hyperten-
sion. With complete genome sequenced and other advances in
genetics and genetic manipulations there is a search for longer-
lasting solution for hypertension meaning better patient compli-
ance, 24-h BP control and possible cost reduction. Some data
are encouraging. Overexpression of ACE2 and AT2R delivered in
viral vectors reduced cardiac remodelling
119 and potentiated BP
control by losartan
120 in rats with chronic Ang II infusion. Adeno-
viral transfer of endothelial NO-synthase and kallikrein genes
improved endothelial dysfunction
121 and cardiac remodelling
122
in SHR. Even more promising results were reported with suppres-
sion of vasoconstrictor expression by the use of cDNA antisense.
In SHR, virally delivered antisense cDNA against ACE
123 and
AT1R
124 reduced respective gene expression and attenuated BP.
The achieved effects were sustained (from 2 weeks up to
9 weeks), but the major concern is the safety and feasibility of
using virus-based delivery systems.
On the other hand a delivery of kallikrein gene in pure plasmid
cDNA p.o. reduced BP in SHR but only for 3–5 days.
125 The
need for repeated delivery would increase the risk of unfavourable
immunologic reactions and also compromise the expected long-
lasting effect. Alternative delivery systems include the use of
antisense oligodeoxynucleotides and small interfering (si)RNA.
Oligodeoxynucleotides against AT1R reduced BP for 18 days in
TGRs,
126 and oligodeoxynucleotides against angiotensinogen
for 5 days in SHR.
127 Small interfering RNA against the
prepro-thyrotropin-releasing hormone in obesity-induced hyper-
tensive rats reduced BP for at least 24 days.
128 Intraventricularly
administered oligodeoxynucleotides targeting renin mRNA
reduced BP for 2 days in SHR.
129
Although being exciting, until more safe and reliable methods of
nucleic acid transfer are established, gene-based therapies are unli-
kely to offer substantial advantage over pharmacological therapies
and will rather provide a valuable experimental tool.
Vaccine-based strategies
An immunological approach might offer similar advantages to those
expected from gene-based strategies. Recently, two antihyperten-
sive vaccines were developed: PMD3117 against Ang I and Cyt006
against Ang II. Despite some excitement the results were rather
disappointing. Although Cyt006 reduced BP in SHR,
130 it achieved
inferior BP reduction (9/4 mmHg)
131 compared with conventional
antihypertensives. In further studies Cyt006 failed to reproduce
this BP reduction, despite shorter dosing intervals and higher anti-
body titres,
132 and PMD3117 did not decrease BP, despite some
degree of RAAS blockade.
133 In addition, the proposed vaccination
at Week 0, 4, and 12
131 or 0, 2, 4, 6, and 10
132 might not be appeal-
ing enough to improve patient compliance. On the other hand,
while previous anti-renin vaccinations were associated with
severe kidney disease,
134,135 PMD3117 and Cyt006 were well
tolerated in Phase I study
130,133 and Cyt006 also blunted early
morning surge in BP.
131
Thus, the vaccination approach seems feasible and might lead to
more effective vaccines or their preventive employment against
CV diseases.
Novel device-based approaches
Controlled breathing
Yoga, meditation, and music decrease sympathetic nervous system
activity, sensitize arterial and cardiopulmonary baroreceptors and
in so doing reduce BP lability and elevated resting BP values. Simi-
larly, slow breathing (,10b.p.m.), especially with a component of
prolonged exhalation, reduced sympathetic nerve trafﬁc while
increasing parasympathetic activity and lowered BP.
136–138
Slow breathing can be achieved by systems that coach patients
to coordinate their breathing with music, which gradually entrains
the respiratory rate downward. The systems require two 15-min
sessions daily, endeavouring to achieve at least 45 min of slow
breathing time per week. A stored record of the session can be
used to assess the patients’ adherence. While there are no
known contraindications and no reported adverse events, this
technique requires a fair amount of discipline and some patients
may view pill taking for BP control to be less time-consuming.
Moreover, poor hearing (frequent in the elderly) complicates
use of this device and a persisting BP-lowering effect seems unli-
kely. Therefore, the device might ﬁnd its use as an adjunctive
Therapeutic perspectives in hypertension 2745antihypertensive treatment complementing other pharmacological
and/or non-pharmacological interventions.
139,140
All in all, the published information on this device is sparse and
the reported studies lack the comparison to techniques such as
meditative relaxation to estimate the contribution of a placebo
effect to the BP response. The suitable candidates for this
therapy might include: (i) the pre-hypertensive or mildly hyperten-
sives, with small BP reductions required; (ii) white coat or labile
hypertensives where behavioural feedback may minimize the
alerting reaction; (iii) as a last resort in patients with resistant
hypertension and/or those with multiple medication sensitivities/
intolerances; (iv) in patients who seek a greater degree of empow-
erment in managing their hypertension.
141 But still, more
persuasive evidence is needed before device guided breathing
can be more generally recommended for BP reduction.
Renal sympathetic denervation
Renal nerve ablation has been advanced as a means to interrupting
the varied mechanistic pathways by which the kidney affects
BP.
142,143 Recently, a percutaneous, catheter-based radiofrequency
ablation for renal sympathetic denervation has been developed.
4,144
Thisprocedurehasbeenevaluatedinacohortstudyof45-treated
patients with treatment resistant hypertension (baseline BP of
177+20/101+15 mmHg). Ofﬁce BPs after the procedure were
reduced by 214/210, 221/210, 222/211, and 227/217 mm
Hgat1,3,6,and12months,respectivelywithfewadverseevents.
145
In another trial Symplicity-2, the safety and effectiveness of
catheter-based renal denervation for reduction of BP was assessed
in 106 patients with resistant hypertension (baseline BP of 178/
96 mm). Ofﬁce-based BP measurements in the renal denervation
group fell by 32+23/12+11 mmHg, whereas they did not
differ from baseline in the control group; again with no serious
procedure-related or device-related complications in this study.
146
This procedure hold considerable promise for the patients with
resistant hypertension but the speciﬁc baseline predictors of
success and head-to-head comparisons with other drugs, such as
aldosterone antagonists, are yet to be determined.
147
Baroreceptor activation
The concept of treating hypertension by prolonged electrical acti-
vation of the carotid baroreﬂex has existed since the mid-1960s
when clinical studies were initiated in patients with severe hyper-
tension refractory to medication.
148–150 Recently, the develop-
ment of the three-component Rheos
w Hypertension System has
resurrected this approach.
151–154
In the Rheos
w DEBuT-HT trial on 45 patients, 72% of 18 patients
(baseline BP of 193+36/111+20 mmHg and heart rate of 74+
13 b.p.m.) treated for 58+6 months achieved at least a 30-mmHg
drop in systolic BP at 4 years (253+9 mmHg) and the average
number of antihypertensive medications used fell from 5.0 to
3.4.
155,156
Currently, the most rigorous study on the Rheos
w device is
underway.
157 The Rheos
w Pivotal Trial (NCT00442286) is an
FDA-approved randomized, double-blind, parallel design phase III
trial with 267 enrolled patients who meet the systolic criteria for
stage 2 drug-resistant hypertension in up to 50 sites in the USA
and Europe.
157 Its current goal is to demonstrate the device’s
efﬁcacy (i.e. BP reduction .10 mmHg 6 months and 1 year after
activation) and acute and long-term safety during implantation
and activation periods.
157 Preliminary subgroup results at 6
months post-implant show a 33.7/15.3 mmHg reduction in systo-
lic/diastolic BP compared with pre-implant BP values (P ,
0.001).
158
Design optimization will likely be needed to make the device a
more market-ready treatment option and will involve surgical tech-
nique reﬁnement, improvements in equipment and, in particular,
extending battery longevity, and/or developing a unilaterally
implantable device.
Figure 3 Recent evolution of dual and triple combinations.
Schematic representation demonstrating the most rational
(thick lines) combinations of classes of antihypertensive agents
according to 2003 guidelines for the management of arterial
hypertension.
165 (A) Adaptation of the upper scheme including
direct renin inhibitors (and omitting a-blockers) demonstrating
dual (red lines) and triple (patterned triangles) combinations
recently approved (since 2003) or in advanced (phase II–III)
development in addition to the previously established combi-
nations (blue thick lines). ARBs, angiotensin II type 1 receptor
blockers; ACE, angiotensin-converting enzyme. In all recent com-
binations calcium blockers are represented by amplodipine
and diuretics by hydrochlorothiazide. Angiotensin-converting
enzyme-inhibitors + b-blockers stand for the combination of
lisinopril + carvedilol, which is a combined b/a1-blocker (B).
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Triple therapies
A considerable legacy, dating to the 1950s, exists for ﬁxed-dose
combination therapies. The rationale to this approach has remained
constantsincethattime:combinationsreduceBPbecauseeachdrug
blocks different effector pathways or the second drug checks
counter-regulatory system activity triggered by the other.
159 In fact
most of the hypertensive patients require at least two drugs to
achieve the target BP values,
160 as recommended for mild-severe
hypertension (≥grade 2) by the current guidelines.
161 The addition
of the diuretic hydrochlorothiazide to AT1R antagonists can mark-
edly enhanced BP reduction
162 and the combination of AT1R antag-
onist with Ca
2+ channel blocker amlodipine was more effective
compared with either drug alone.
163 In addition to superior BP
control,theadditionofAT1Rantagonistmightreducetheriskofper-
ipheral oedema caused by amlodipine therapy
163 or hypokalaemia
evokedbydiureticadministration.
164 Since 2000,10 new ﬁxed-dose
combinations were approved including AT1R antagonist (or
ACE-Inhibitor or renin inhibitor) + hydrochlorothiazide (and/or
amlodipine); AT1R antagonist + renin inhibitor; ACE-Inhibitor +
b-blocker; and amlodipine + statin
1,165 and their efﬁcacy and
safetyhasbeenestablished.However,thetwo-drugﬁxed-dosecom-
bination era is now rapidly morphing to three drug combinations.
The investigational triple therapies are composed of a RAAS inhibi-
tor, amlodipine, and hydrochlorothiazide.
1,166,167 In hypertensive
patients with a mean sitting diastolic BP of .100 mmHg such
triple-therapy (valsartan + amlodipine + hydrochlorothiazide)
loweredBPby40/25 mmHgwhichwassigniﬁcantlymorecompared
with the any two-drug combination (Figure 3).
166,168
Although, unsurprisingly, the triple combinations provided
more profound BP reduction and higher BP control rate
without compromising the tolerability or safety,
169 the question
remains whether combination therapy should be administered in
ﬁxed-dose combinations or not. The advantages of single pill
regimens are (i) more simple administration, (ii) more rapid
achievement of BP goal than by gradual titration; (iii) existing
simple and rapid full dose up-titration schemes; (iv) better
patient adherence to therapy; (v) potential for fewer non-
responders to a three-drug choice. On the other hand, their
disadvantages include (i) higher risk of dose-independent
adverse reactions, (ii) loss of dose ﬂexibility, with possibly inap-
propriate dosing,
160,168 and (iii) the inability to introduce a
chronotherapeutic approach.
170 Hence, individually tailored
therapy is traded for reduced costs and simpliﬁcation.
More studies on novel combinations including aliskiren as RAAS
inhibitor or chlorthalidone as diuretic are on the way and the rec-
ommendations on triple therapy should become more speciﬁc.
After more evidence is provided, patients that will mostly beneﬁt
from single-pill regimens can be identiﬁed, while in others the
therapy may still be individually adjusted.
Conclusions
Difﬁcult to treat hypertension is a commonly observed problem
globally. Available, conventional therapies have been the mainstay
of therapy for hypertension but still have been variably successful
in bringing BP to goal. A number of other drug classes have been
used as complementary therapies for BP reduction including
central a2-receptor agonists, peripheral a1-receptor antagonists,
and direct vasodilators. This array of medications has now been
complemented by a number of new approaches of a medication,
immunologic, and device nature. Many of them are being tested
and the basis for their use reﬁned. In addition, therapeutic regi-
mens are being ﬁne-tuned and several novel ﬁxed-dose combi-
nations were recently established. However, therapies such as
aldosterone synthase inhibition, endothelin receptor antagonism,
and gene and vaccine based-strategies have evolved more slowly
than expected and point to the difﬁculty in bringing a new
therapy for hypertension to market.
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